|
|
Join Us!
The First Interdisciplinary Prostate Cancer Congress
Bridging the Gap Across Disciplines
and the Prostate Cancer Treatment Continuum
in an Era of Novel Therapeutics and Emerging Treatment Paradigms
Who should attend? Practicing urologists, radiation oncologists, and medical oncologists who treat prostate cancer in their patients.
ArcMesa Educators, a fully-accredited provider of high quality and relevant continuing medical education (CME) programs, is proud to announce the convening of its first annual Interdisciplinary Prostate Cancer (IPC) Congress. This full-day CME initiative entitled “Bridging the Gap Across Disciplines and the Prostate Cancer Treatment Continuum in an Era of Novel Therapeutics and Emerging Treatment Paradigms” will be the first in a series of innovative, interactive CME activities.
Prostate
cancer is the most common noncutaneous type of cancer among men In
the United States, there will be an estimated 219,000 new cases and
approximately 27,000 deaths from this disease in 2008. On March 8,
2008, ArcMesa Educators, a fully accredited provider of continuing
medical education (CME), will sponsor its inaugural Interdisciplinary
Prostate Cancer Congress (IPCC) at the Millennium Broadway Hotel in
New York City. This full-day CME initiative entitled Bridging the
Gap Across Disciplines and the Prostate Cancer Treatment Continuum in
an Era of Novel Therapeutics and Emerging Treatment Paradigms will be the first CME activity specifically dedicated to addressing
the differences that currently exist between urologists’, radiation
oncologists’, and medical oncologists’ approaches to treating
prostate cancer. The urgency for this CME initiative is readily
reflected by the elimination of a dedicated prostate cancer meeting
by The American Society of Clinical Oncology (ASCO) in favor of one
broadly focused on genitourinary disease management.
Leonard
Gomella, MD and Daniel Petrylak, MD will serve as co-chairs for the
IPCC. In addition, E. David Crawford, MD, Robert Dreicer, MD, Mack
Roach III, MD, Howard Sandler, MD, and Oliver Sartor, MD will serve
as faculty members for this educational initiative. These
world-renowned thought leaders have been brought together to foster
consensus about the best management of prostate cancer from the
vantage point of interdisciplinary care teams. Among several topics
of vital interest to these groups of clinicians, the IPCC will
address hormonal therapies, imaging and staging, surgical advances,
radiation therapies, and emerging multi-modal therapies. The IPCC
will conclude with a set of interactive case-based presentations
designed to highlight multidisciplinary approaches for the management
of prostate cancer with the overall goal of improving patient
outcomes.
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ArcMesa Educators designates this educational activity for a maximum of 7 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Daniel P. Petrylak, MD - Co-Chair
Co-Director of Oncology Clinical Trials Network [OCTN]
Assistant Professor of Medicine
Director of the Genitourinary Oncology Program in the Division of Medical Oncology
Columbia University College of Physicians and Surgeons
New York, New York
Leonard G. Gomella, MD - Co-Chair
The Bernard W. Godwin Professor of Prostate Cancer
Chairman Department of Urology
Associate Director of Clinical Affairs
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania
Urology Chair for Radiation Therapy Oncology Group (ROTG)
E. David Crawford, MD
Professor of Surgery, Urology, and Radiation Oncology
Head, Urologic Oncology
E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology
University of Colorado Health Sciences Center
Denver, Colorado
Robert Dreicer, MD
Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
Mack Roach III, MD, FACR
Professor and Chair, Radiation Oncology
Professor, Urology, UCSF Investigator
Comprehensive Minority Institution/Cancer Center Partnership
San Francisco State University and UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Howard Sandler, MD, MS
Newman Family Professor and Senior Associate Chair, Department of Radiation Oncology
Professor, Department of Urology
University of Michigan
Ann Arbor, Michigan
Oliver Sartor, MD
Piltz Professor of Cancer Research
Departments of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana
Daniel P. Petrylak, MD - Co-Chair
Consultant, Grant/Research Support recipient – GPC Biotech, sanofi-aventis, Celgene, Cell Genesys, Dendreon
Honorarium – sanofi-aventis
Leonard G. Gomella, MD - Co-Chair
Speakers’ Bureau – AstraZeneca
Consultant, Investigator – GlaxoSmithKline
Investigator - Dendreon
E. David Crawford, MD
Dr. Crawford has indicated he has nothing to disclose relative to this activity.
Robert Dreicer, MD
Grant/Research Support recipient – Bayer, Celgene, Lilly, sanofi-aventis
Honorarium – Merck, Novartis
Mack Roach III, MD, FACR
Grant/Research Support recipient - GlaxoSmithKline
Consultant - AstraZeneca
Speakers’ Burearu - Siemens, TAP Pharma
U-56 Grant - NCI
Handbook of Evidence-based Radiation Oncology - Springer
Howard Sandler, MD, MS
Honorarium – AstraZeneca, GPC Biotech, Amgen
Oliver Sartor, MD
Advisor or Review Panel member, Consultant – Cytogen, Algeta, GPC-Biotech, sanofi-aventis, GlaxoSmithKline, Ausio
The employees of ArcMesa Educators have nothing to disclose relative to this activity.
• Prostate cancer guidelines and their differences
• Advances in the management of prostate cancer
• Current drug development including multi-modal therapeutic approaches
• Imaging (role of staging, CT, MRI, SPECT, immunoscintigraphy, fusion imaging and others)
• Surgical Advances (focal therapy, robot-assisted vs. open radical prostatectomy, cryotherapy)
• Immunotherapies (active and passive)
• Technical innovations in Radiation Therapy (adjuvant, brachytherapy, proton therapy, IMRT, IGRT, EBRT, tumor localization system)
• Active Surveillance
After completing this activity, participants should be able to:
• Review the current treatment options for patients with localized, androgen-dependent, and hormone refractory prostate cancer.
• Identify the disparities among current practice guidelines for the treatment of patients with prostate cancer.
• Evaluate the results of recent clinical trials investigating the efficacy and safety of emerging agents for the treatment of prostate cancer.
• Formulate an interdisciplinary plan for the treatment and management of patients with prostate cancer.
Sponsored by  | Supported by an
educational grant from  |
|
|
